Genome-wide analysis of DNA 5-hydroxymethylcytosine in uremia patients using hMeDIP-chip
10.3760/cma.j.issn.1007-7480.2015.09.010
- VernacularTitle:应用hMeDIP-chip技术分析系统性红斑狼疮患者5-羟甲基胞嘧啶状态
- Author:
Weiguo SUI
;
Qiupei TAN
;
Hua LIN
;
Xingchao LIU
;
Jiejing CHEN
;
Wen XUE
;
Yong DAI
- Publication Type:Journal Article
- Keywords:
Lupus erythematosus,systemic;
hMeDIP-seq;
5-hydroxymethylcytosine
- From:
Chinese Journal of Rheumatology
2015;19(9):618-622
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the role of the 5-hydroxymethylcytosine (5-hmC) DNA modification in the onset of systemic lupus erythemosus (SLE),we compared tihe levels 5-hmC between SLE patients and normal controls.Methods With informed consent,whole blood was obtained from patients,and genomic DNA was extracted.Using hMeDIP-seq analysis and validation by quantitative real-time quantitative polymerase chain reaction (RT-PCR),we identified the differentially hydroxymethylated regions that were associated with SLE.Results There were 1 701 genes with significantly different 5-hmC levels at the promoter region in the SLE patients compared with the normal controls.The CpG islands of 3 826 genes showed significant difference at 5-hmC levels in SLE patients compared with the normal controls.Out of the differentially hydroxymethylated genes,three were selected for validation,including TREX1,CDKN1A,and CDKN1B.The hydroxymethylation levels of these three genes were confirmed by quantitative RT-PCR.Conclusion Our studies indicate that there are significant alterations of 5-hmC in SLE patients;these differentially hydroxymethylated genes may contribute to the pathogenesis of SLE.Such novel findings show the significance of 5-hmC as a potential biomarker or promising target for epigenetic-based SLE therapies.
